Acth and Secondary progressive multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Secondary progressive multiple sclerosis is reported as a side effect among people who take Acth (corticotropin), especially for people who are female, 60+ old, also take Xeljanz, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Secondary progressive multiple sclerosis when taking Acth. It is created by eHealthMe based on reports of 5,384 people who have side effects when taking Acth from the FDA, and is updated regularly.

What is Acth?

Acth has active ingredients of corticotropin. eHealthMe is studying from 5,402 Acth users. Check the latest studies of Acth.

What is Secondary progressive multiple sclerosis?

Secondary progressive multiple sclerosis (a stage of ms which comes after relapsing remitting ms in many cases) is found to be associated with 139 drugs and 131 conditions by eHealthMe. Check the latest studies of Secondary progressive multiple sclerosis.

On Jul, 15, 2026

5,384 people reported to have side effects when taking Acth.
Among them, 14 people (0.26%) have Secondary progressive multiple sclerosis.

Could Acth cause Secondary progressive multiple sclerosis?

Among these 14 people:

What is the gender of people who have Secondary progressive multiple sclerosis when taking Acth? *

female: 100 %
male: 0.0 %

What is the age of people who have Secondary progressive multiple sclerosis when taking Acth? *

What are other drugs people take besides Acth? *

What are other side effects people have besides Secondary progressive multiple sclerosis? *

Drug Ineffective: 10 people, 71.43%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 9 people, 64.29%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 8 people, 57.14%
Hoarseness Or Changing Voice: 7 people, 50.00%
Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 7 people, 50.00%
Trigeminal Neuralgia (a painful condition of the nerve responsible for most facial sensation): 7 people, 50.00%
Movement - Uncoordinated: 7 people, 50.00%
Fall: 2 people, 14.29%
Hearing Loss: 1 person, 7.14%
Head Injury: 1 person, 7.14%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 9 people, 64.29%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 4 people, 28.57%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 7.14%
Hypotension (abnormally low blood pressure): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Acth and have Secondary progressive multiple sclerosis?

- Check whether Secondary progressive multiple sclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Acth:

Acth (5,402 reports)

Secondary progressive multiple sclerosis treatments and more:

Secondary progressive multiple sclerosis (11,840 reports)

How severe was Secondary progressive multiple sclerosis and when was it recovered:

Secondary progressive multiple sclerosis in Acth

Expand to all the drugs that have ingredients of corticotropin:

Secondary progressive multiple sclerosis and drugs with ingredients of corticotropin

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Acth:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Secondary progressive multiple sclerosis:

Secondary progressive multiple sclerosis (139 drugs)

Browse all the conditions that are associated with Secondary progressive multiple sclerosis:

Secondary progressive multiple sclerosis (131 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on corticotropin (the active ingredients of Acth) and Acth (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.